Josef Leibold

3.6k total citations · 2 hit papers
13 papers, 2.0k citations indexed

About

Josef Leibold is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Josef Leibold has authored 13 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Josef Leibold's work include CAR-T cell therapy research (5 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Josef Leibold is often cited by papers focused on CAR-T cell therapy research (5 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Josef Leibold collaborates with scholars based in United States, Germany and Switzerland. Josef Leibold's co-authors include Yu-Jui Ho, Judith Feucht, Scott W. Lowe, Michel Sadelain, Amanda Kulick, Direna Alonso‐Curbelo, Corina Amor, Theodoros Giavridis, Jacob A. Boyer and Vladimir Ponomarev and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Josef Leibold

12 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Senolytic CAR T cells reverse senescence-associated pathologies

2020 724 citations Corina Amor, Judith Feucht et al. Nature profile →
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

2018 373 citations Judith Feucht, Jie Sun et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josef Leibold United States	9	833	819	671	539	262	13	2.0k
Amanda Kulick United States	9	640 0.8×	518 0.6×	491 0.7×	527 1.0×	123 0.5×	13	1.6k
Janelle Simon United States	11	993 1.2×	727 0.9×	504 0.8×	457 0.8×	106 0.4×	13	2.0k
Direna Alonso‐Curbelo United States	14	947 1.1×	540 0.7×	595 0.9×	594 1.1×	97 0.4×	20	1.9k
Karin Schaeuble Switzerland	14	766 0.9×	1.1k 1.3×	1.3k 2.0×	477 0.9×	69 0.3×	17	2.4k
María V. Guijarro United States	17	1.4k 1.6×	678 0.8×	566 0.8×	800 1.5×	41 0.2×	31	2.4k
Jamila Laoukili Netherlands	20	1.7k 2.0×	548 0.7×	293 0.4×	256 0.5×	77 0.3×	30	2.5k
Michael Milyavsky Israel	23	1.5k 1.8×	725 0.9×	251 0.4×	283 0.5×	53 0.2×	47	2.1k
Eva González‐Suárez Spain	27	1.5k 1.8×	1.2k 1.5×	251 0.4×	800 1.5×	49 0.2×	49	2.6k
Amber Giles United States	16	673 0.8×	817 1.0×	818 1.2×	221 0.4×	113 0.4×	26	2.1k

Countries citing papers authored by Josef Leibold

Since Specialization

Citations

This map shows the geographic impact of Josef Leibold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Leibold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Leibold more than expected).

Fields of papers citing papers by Josef Leibold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef Leibold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Leibold. The network helps show where Josef Leibold may publish in the future.

Co-authorship network of co-authors of Josef Leibold

This figure shows the co-authorship network connecting the top 25 collaborators of Josef Leibold. A scholar is included among the top collaborators of Josef Leibold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef Leibold. Josef Leibold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Rausch, Mary, Katrin Bartels, & Josef Leibold. (2025). Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanisms. Signal Transduction and Targeted Therapy. 10(1). 17–17.

Leibold, Josef, Kaloyan M. Tsanov, Corina Amor, et al.. (2024). Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nature Cancer. 5(2). 315–329. 12 indexed citations

Paffenholz, Stella, Camilla Salvagno, Yu-Jui Ho, et al.. (2022). Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proceedings of the National Academy of Sciences. 119(5). 50 indexed citations

Amor, Corina, Judith Feucht, Josef Leibold, et al.. (2020). Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 583(7814). 127–132. 724 indexed citations breakdown →

Ruscetti, Marcus, John P. Morris, Riccardo Mezzadra, et al.. (2020). Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 181(2). 424–441.e21. 281 indexed citations

Sanghvi, Viraj R., Josef Leibold, Marco Mina, et al.. (2019). The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Cell. 178(4). 807–819.e21. 113 indexed citations

Ruscetti, Marcus, Josef Leibold, Matthew J. Bott, et al.. (2018). NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 362(6421). 1416–1422. 268 indexed citations

Feucht, Judith, Jie Sun, Justin Eyquem, et al.. (2018). Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine. 25(1). 82–88. 373 indexed citations breakdown →

Lee, Derek, Mingjing Xu, David Kung‐Chun Chiu, et al.. (2018). Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology. 69(4). 1768–1786. 130 indexed citations

10.

Feucht, Judith, Jie Sun, Justin Eyquem, et al.. (2018). Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency. Blood. 132(Supplement 1). 1412–1412. 1 indexed citations

11.

André, Maya C., Josef Leibold, Philaretos C. Kousis, et al.. (2016). An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia. 31(2). 459–469. 48 indexed citations

12.

Feucht, Judith, et al.. (2014). Differential expression of T_HELPER1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus‐specific T cells following re‐stimulation. Transplant Infectious Disease. 16(5). 713–723. 1 indexed citations

13.

Leibold, Josef, Judith Feucht, Stefan Stevanović, et al.. (2012). Induction of Thelper1-driven Antiviral T-cell Lines for Adoptive Immunotherapy Is Determined by Differential Expression of IFN-γ and T-cell Activation Markers. Journal of Immunotherapy. 35(9). 661–669. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact